Universe Pharmaceuticals (UPC) Debt to Equity (2020 - 2025)

Universe Pharmaceuticals has disclosed Debt to Equity across 6 years of filings, most recently posting $0.04 for Q3 2025.

• Debt to Equity for Q3 2025 came in at $0.04, down 78.63% year-over-year; the trailing twelve-month figure through Sep 2025 was $0.04 (down 78.63% YoY), and the FY2025 annual result was $0.04, down 78.63% from the prior year.
• Debt to Equity came in at $0.04 for Q3 2025 at Universe Pharmaceuticals, down from $0.18 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.28 in Q1 2024 to a low of $0.0 in Q3 2022.
• The 5-year median for Debt to Equity is $0.02 (2021), against an average of $0.08.
• Across the five-year window, Debt to Equity plunged 100.0% in 2021 and soared 96748.37% in 2023, its largest moves.
• Universe Pharmaceuticals' Debt to Equity stood at $0.0 in 2021, then sank by 77.21% to $0.0 in 2022, then surged by 104.93% to $0.0 in 2023, then surged by 89530.22% to $0.18 in 2024, then slumped by 78.63% to $0.04 in 2025.
• The last three Debt to Equity figures came in at $0.04 (Q3 2025), $0.18 (Q3 2024), and $0.28 (Q1 2024), per Business Quant data.